TABLE 2.

Comparison of recombinant LigB-based immunoblot assay with standard diagnostic tests for leptospirosis

Phase of illness and time period after onsetNo. of samples testedResults for standard diagnostic evaluationrLigB immunoblot (no. of positive reactions [%]) for:
Median maximum reciprocal MAT titer (range)No. of samples with reciprocal MAT titer of ≥100 (%)IgM ELISA (no. of positive reactions [%])IgMIgG
Acute phase (n = 95)a
    2 to 6 days210 (0-3,200)7 (33)11 (52)17 (81)13 (62)
    7 to 11 days55400 (0-6,400)35 (64)47 (85)52 (94)51 (93)
    12 to 23 days19800 (0-6,400)15 (79)14 (74)18 (95)17 (89)
Early convalescent phase (n = 95)a
    18 to 28 days423,200 (800-25,600)42 (100)41 (98)37 (88)40 (95)
    29 to 36 days331,600 (400-12,800)33 (100)32 (97)25 (76)33 (100)
    37 to 113 days201,600 (200-6,400)20 (100)20 (100)7 (35)20 (100)
Late convalescent phase (n = 58)b
    4 to 23 mos24400 (0-800)20 (83)23 (96)4 (17)13 (54)
    24 to 47 mos17400 (100-1,600)17 (100)7 (41)1 (6)3 (18)
    48 to 72 mos17200 (200-800)15 (88)5 (29)1 (6)3 (18)
  • a Paired samples were obtained from 95 leptospirosis cases (n) in Salvador, Brazil. Early-convalescent-phase samples were obtained more than 14 days and less than 4 months after collection of acute-phase samples.

  • b Late-convalescent-phase samples were obtained from leptospirosis patients 4 months to 72 months after discharge from hospital.